niacinamide and imetelstat

niacinamide has been researched along with imetelstat in 94 studies

Research

Studies (94)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	20 (21.28)	29.6817
2010's	74 (78.72)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alva, G; Bready, J; Cattley, R; Chen, D; Coxon, A; DeMelfi, T; Diaz, Z; Estrada, J; Gan, Y; Kaufman, S; Kendall, R; Kumar, G; Meyer, J; Montestruque, S; Neervannan, S; Patel, V; Polverino, A; Radinsky, R; Starnes, C; Talvenheimo, J; Tasker, A; Wang, L	1
von Mehren, M	1
de Jonge, M; Verweij, J	1
Bass, MB; Benjamin, R; Chang, DD; Herbst, RS; Koutsoukos, A; Kurzrock, R; Mulay, M; Ng, C; Polverino, A; Purdom, M; Rosen, LS; Silverman, J; Sun, YN; Van Vugt, A; Wiezorek, JS; Xu, RY	1
Antoch, G; Ebeling, P; Frilling, A; Grabellus, F; Schmid, KW; Sheu, SY; Worm, K	1
Bui, B; Italiano, A	1
Apice, G; Bruni, GS; Caponigro, F; Iaffaioli, RV; Milano, A	1
Lee, CB; Socinski, MA	1
Sherman, SI	2
Chen, L; Heath, EI; Ingram, M; Lorusso, P; Malburg, L; McGreivy, J; Melara, R; Pilat, MJ; Sun, YN; Wiezorek, J; Yan, L	1
Bastholt, L; Droz, JP; Eschenberg, MJ; Hofmann, M; Juan, T; Licitra, L; Martins, RG; Schlumberger, MJ; Sherman, SI; Stepan, DE; Sun, YN; Wirth, LJ	1
Döme, B; Magyar, M	1
Lipton, L; McCoy, S; McGreivy, J; Price, TJ; Rosenthal, MA; Sun, YN	1
Azad, A; Herbertson, RA; Mitchell, PL; Pook, D; Tebbutt, NC; White, S	1
Diaz-Cano, SJ	1
Belmontes, B; Bush, T; Caenepeel, S; Coxon, A; Hughes, P; Kaufman, S; Kendall, R; Patel, V; Polverino, A; Radinsky, R; Rex, K; Rottman, JB; Saffran, D; Tasker, A	1
Kiselyov, AS; Semenov, VV; Semenova, M	1
Bastholt, L; Daumerie, C; Droz, JP; Elisei, R; Eschenberg, MJ; Jarzab, B; Juan, T; Locati, LD; Martins, RG; Pacini, F; Schlumberger, MJ; Sherman, SI; Stepan, DE; Sun, YN; Wirth, LJ	1
Baba, H; Doi, T; Kanda, T; Komatsu, Y; Koseki, M; Murakami, K; Nishida, T; Sawaki, A; Sun, YN; Yamada, Y	1
Marian, CO; Shay, JW; Wright, WE	1
Blumenschein, GR; Gladish, G; McGreivy, J; O'Rourke, T; Parson, M; Reckamp, K; Sandler, A; Stephenson, GJ; Sun, YN; Ye, Y	1
Bass, MB; Fujisaka, Y; Fujiwara, Y; Seki, M; Shimizu, T; Sun, YN; Tamura, T; Watanabe, H; Yamada, K; Yamada, Y; Yamamoto, N	1
Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P	1
Boockvar, JA; Hofstetter, CP	1
Gupta, N; Hashizume, R	1
Anderson, A; Beaupre, DM; Deng, H; Leitch, IM; Oliner, KS; Park, DJ; Rosen, PJ; Shubhakar, P; Sweeney, CJ; Yee, LK; Zhu, M	1
Armstrong, EA; Bussink, J; Coxon, A; Harari, PM; Iida, M; Kozak, KR; Kruser, TJ; Polverino, A; van der Kogel, AJ; Wheeler, DL	1
Baher, A; Baron, W; Bush, TL; Caenepeel, S; Hughes, PE; Juan, T; Manoukian, R; Polverino, A; Renshaw-Gegg, L; Tasker, AS	1
Bass, MB; Davis, MT; Hei, YJ; Khoo, HM; Kivman, L; Notari, KH; Patterson, SD; Peach, M; Schlumberger, MJ; Sherman, SI	1
Baker, L; Benjamin, RS; Blay, JY; Bui, BN; Duyster, J; Hartmann, JT; McCoy, S; Reichardt, P; Rosen, LS; Schöffski, P; Schuetze, S; Skubitz, K; Stepan, DE; Sun, YN; Van Oosterom, A	1
Bruno, R; Claret, L; Kuchimanchi, M; Lu, JF; Melara, R; Sun, YN; Sutjandra, L	1
Bruno, R; Claret, L; Lu, JF; Sun, YN	1
Costanzo, R; Daniele, G; Di Maio, M; Giordano, P; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Riccardi, MG; Rocco, G	1
Bassett, E; Buseman, CM; Go, NF; Harley, C; Joseph, I; Pattamatta, P; Shay, JW; Tressler, R; Wright, WE	1
Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R	1
Beck, JT; Blumenschein, GR; Hei, YJ; Kabbinavar, F; Kracht, K; Lakshmaiah, K; Menon, H; Mok, TSK; Reckamp, K; Schwartzberg, L; Sikorski, R; Stephenson, J; Sun, YN	1
Bready, J; Canon, J; Coxon, A; Estrada, J; Hughes, P; Kaufman, S; Kendall, R; Osgood, T; Polverino, A; Radinsky, R; Wang, L	1
Buzdar, AU	1
Adewoye, H; Adrover, E; Alba, E; Almel, S; Baños, A; Cabaribere, D; Crown, J; Eiermann, W; Hei, YJ; Hurvitz, S; Jagiełło-Gruszfeld, A; Kennedy, MJ; Lang, I; Latreille, J; Lemmerick, Y; Lindsay, MA; Mackey, JR; Martin, M; Moroose, R; Munoz, M; Pienkowski, T; Pinter, T; Priou, F; Provencher, L; Ramos, M; Roche, H; Rolski, J; Rupin, M; Snyder, R	1
Blumenschein, GR; Raghav, KP	1
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES	1
Adewoye, AH; Desai, J; Johnson, J; Kotasek, D; McCoy, S; Price, T; Siu, LL; Sun, YN; Tebbutt, N; Welch, S	1
Döme, B; Török, S	1
Herbst, RS; Morgensztern, D	1
Banaclocha, NM; Blackhall, F; Ciuleanu, TE; Dediu, M; Galimi, F; Galiulin, R; Hei, YJ; Ichinose, Y; Kubota, K; McCoy, S; Papai-Szekely, Z; Park, K; Pirker, R; Scagliotti, GV; Spigel, DR; Sydorenko, O; Vynnychenko, I; Yao, B	1
Adewoye, AH; Chan, A; De Boer, RH; Kaufman, PA; Koczwara, B; Kotasek, D; Mainwaring, P; Melara, R; Sikorski, R; White, S; Ye, Y	1
Bergqvist, M; Ekman, S; Gryaznov, S; Karlsson, K; Nordfjäll, K; Paulsson-Karlsson, Y; Qvarnström, F; Simonsson, M; Smavadati, S; Wu, X	1
Bruno, R; Claret, L; Hei, YJ; Hsu, CP; Lu, JF; Sun, YN	1
Coxon, A; Kaufman, S; Polverino, A; Saffran, D; Schmidt, J; Starnes, C; Sweet, H; Wang, H; Weishuhn, D; Xu, M; Ziegler, B	1
Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S	1
Williams, SC	1
Alpaugh, RK; Bonebrake, AJ; Godwin, AK; Gold, MA; Hanjani, P; Hu, W; Lankes, HA; Mannel, RS; Modesitt, SC; Schilder, RJ; Sill, MW; Sood, AK	1
Akcali, KC; Can, A; Dikmen, ZG; Gryaznov, S; Kletsas, D; Mender, I; Ozgunes, N; Senturk, S; Shay, JW	1
Belman, ND; Boccia, RV; Hei, YJ; Hsu, CP; Hurwitz, HI; Lipton, L; McCoy, S; Price, TJ; Rosen, LS; Stephenson, JJ; Tebbutt, NC; Wirth, LJ	1
Aloyz, R; Assouline, SE; Autexier, C; Chu, TW; Gryaznov, SM; Johnston, JB; Lees-Miller, SP; Martinez-Marignac, V; Shawi, M; Yu, Y	1
Ahern, CH; Blaney, SM; Drissi, R; Fouladi, M; Ingle, AM; Lin, T; Muscal, JA; Panditharatna, E; Reid, JM; Thompson, PA; Weigel, BJ	1
Hei, YJ; Hsia, TC; Ichinose, Y; Kim, JH; Kim, SW; Kubota, K; Li, RK; Lim, WT; Park, K; Scagliotti, G; Shinkai, T; Spigel, D; Takeda, K; Tiangco, BJ; Yao, B; Yau, S	1
Bruno, R; Claret, L; Hsu, CP; Lu, JF; Sun, YN	1
Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ	1
Ambudkar, SV; Chen, ZS; Fung, KL; Kathawala, RJ; Kumar, P; Patel, A; Shukla, S; Talele, TT; Wang, YJ; Zhang, YK	1
Alama, A; Barletta, G; Biello, F; Boccardo, F; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Truini, A; Vanni, I	1
Adamski, J; Agnihotri, S; Barszczyk, M; Buczkowicz, P; Castelo-Branco, P; Dirks, PB; Elizabeth, C; Golbourn, B; Hawkins, C; Li, XN; Luu, B; Mack, SC; Mangerel, J; Morrison, A; Nethery-Brokx, K; Pajovic, S; Ramaswamy, V; Remke, M; Rutka, JT; Tabori, U; Taylor, MD; Van Meter, T; Yu, M	1
Blackhall, F; Hei, YJ; McCoy, S; Novello, S; Scagliotti, GV; Schneider, CP; Spigel, DR; Sydorenko, O; Volovat, C; Vynnychenko, I	1
Cho, WK; Choi, H; Kang, S; Park, KC; Rho, CR; Yang, KJ	1
Bass, MB; Chan, SS; Davis, GJ; Davis, MT; Hei, YJ; Kaesdorf, BA; Patterson, SD; Yao, B; Ye, Y	1
Bobb, D; Dome, JS; He, J; Hu, Y; Lu, Y	1
Bassett, E; Blais, N; Burington, B; Chiappori, AA; Gadgeel, S; Hager, S; Hart, L; Kolevska, T; Rarick, M; Reck, M; Schiller, JH; Spigel, DR; Von Pawel, J	1
Armstrong, SA; Austin, R; Bagger, FO; Bruedigam, C; Bullinger, L; Guignes, S; Heidel, FH; Hill, GR; Lane, SW; Lee, E; Lock, RB; Moore, AS; Paine Kuhn, C; Riyat, S; Song, A; Vu, T; Williams, DA	1
Bass, MB; Friberg, G; Hong, DS; Kurzrock, R; Mulay, M; Rasmussen, E; Rosen, LS; Wu, BM; Zhong, ZD	1
Abid, S; Adnot, S; Amsellem, V; Blasco, MA; Boczkowski, J; Delcroix, M; Derumeaux, G; Dubois-Randé, JL; Gary-Bobo, G; Houssaïni, A; Lipskaia, L; Marcos, E; Mouraret, N; Parpaleix, A; Quarck, R	1
Colevas, AD; Gruber, JJ	1
Herbert, BS; Koziel, JE	1
Adams, TE; Budiman, S; Devlin, M; Donoghue, JF; Dubljevic, V; Greenall, SA; Johns, TG; Street, I; Van Sinderen, M	1
Burris, HA; Chen, L; Goldstein, D; Hsu, CP; Hurwitz, H; Kotasek, D; Schwartzberg, LS; Stephenson, J; Tebbutt, N; Warner, DJ	1
Bobb, D; Dome, JS; He, J; Hill, DA; Hu, Y	1
Eriksson, LA; Gao, C; Grøtli, M	1
Alphonse, G; Battiston-Montagne, P; Bolbos, R; El Hamdani, B; Ferrandon, S; Gryaznov, SM; Honnorat, J; Langlois, JB; Malleval, C; Manas, P; Poncet, D; Rodriguez-Lafrasse, C	1
Gemma, A; Miyanaga, A	1
Begna, KH; Finke, CM; Gangat, N; Hanson, CA; Laborde, RR; Lasho, TL; Pardanani, A; Patnaik, MM; Schimek, L; Tefferi, A; Wang, X; Wassie, E; Zblewski, DL	1
Baerlocher, GM; Burington, B; Daskalakis, M; McDevitt, MA; Odenike, O; Oppliger Leibundgut, E; Ottmann, OG; Röth, A; Snyder, DS; Spitzer, G; Stuart, M	1
Covell, LL; Ganti, AK	1
Bandaru, S; Dunna, NR; Girdhar, A; Hussain, T; Kandula, V; Nayarisseri, A; Pudutha, A	1
Cully, M	1
Al-Kali, A; Begna, KH; Hanson, CA; Lasho, TL; Patnaik, MM; Rizo, A; Tefferi, A; Wan, Y	1
Altun, A; Ataseven, H; Kaya, TT; Koyluoglu, G; Turgut, NH	1
Chen, LW; Man, RJ; Zhu, HL	1
Frink, RE; Gazdar, AF; Minna, JD; Peyton, M; Schiller, JH; Shay, JW	1
Boyett, J; Daryani, VM; Dhall, G; Dorris, K; Drissi, R; Fisher, P; Fouladi, M; Goldman, S; Hummel, TR; Kumar, SS; Li, S; Lin, T; Miles, L; Packer, R; Pollack, IF; Poussaint, TY; Salloum, R; Stevenson, C; Stewart, CF	1
Kim, KH; Kim, SB; Kim, TN; Lee, KH; Song, J	1
Guo, Z; Kuang, Z; Tan, G; Wei, Q; Wu, X; Yang, G; Yang, S; Zhang, J	1
Crispino, JD; Eng, K; Hoffman, R; Iancu-Rubin, C; Kraus, T; Mosoyan, G; Ye, F	1
Irwin, DC; Loomis, Z; Maltzahn, J; Tarshis, S	1
Asato, T; Cho, EK; Hara, K; Hayashi, H; Hida, T; Ichinose, Y; Kaneda, H; Kato, T; Kubota, K; Lee, KH; Lin, CB; Nakagawa, K; Oshita, F; Park, K; Tanaka, H; Yamada, K; Yang, JC; Yoh, K; Yoshioka, H	1

Reviews

23 review(s) available for niacinamide and imetelstat

Article	Year
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clinical colorectal cancer, 2006, Volume: 6 Suppl 1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Niacinamide; Oligonucleotides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sirolimus; Staurosporine; Sunitinib; Thiazoles	2006
Multitarget tyrosine kinase inhibition: [and the winner is...]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jun-10, Volume: 25, Issue:17 Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Humans; Indoles; Neoplasms; Niacinamide; Oligonucleotides; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Research Design	2007
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications]. Bulletin du cancer, 2008, Volume: 95, Issue:1 Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles	2008
Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives. Reviews on recent clinical trials, 2006, Volume: 1, Issue:1 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Dioxoles; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Niacinamide; Oligonucleotides; Phthalazines; Piperazines; Proto-Oncogene Mas; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Tetrahydroisoquinolines; Trabectedin	2006
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials. Reviews on recent clinical trials, 2007, Volume: 2, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome	2007
Early clinical studies of novel therapies for thyroid cancers. Endocrinology and metabolism clinics of North America, 2008, Volume: 37, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma; Clinical Trials as Topic; Drug Delivery Systems; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Thyroid Neoplasms	2008
[Tumor vasculature as a therapeutic target in non-small cell lung cancer]. Magyar onkologia, 2008, Volume: 52, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones	2008
Tyrosine kinase inhibitors and the thyroid. Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:6 Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms	2009
Targeted molecular therapies in thyroid carcinoma. Arquivos brasileiros de endocrinologia e metabologia, 2009, Volume: 53, Issue:9 Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms	2009
Telomerase inhibitors for the treatment of brain tumors and the potential of intranasal delivery. Current opinion in molecular therapeutics, 2010, Volume: 12, Issue:2 Topics: Administration, Intranasal; Animals; Blood-Brain Barrier; Brain Neoplasms; Enzyme Inhibitors; Humans; Indoles; Neoplasms; Neural Pathways; Niacinamide; Oligonucleotides; Telomerase	2010
New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development. Expert opinion on investigational drugs, 2010, Volume: 19, Issue:12 Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Drug Discovery; Humans; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Quinazolines; Randomized Controlled Trials as Topic	2010
In pursuit of new anti-angiogenic therapies for cancer treatment. Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment	2011
Motesanib and advanced NSCLC: experiences and expectations. Expert opinion on investigational drugs, 2011, Volume: 20, Issue:6 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biological Availability; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Humans; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Vascular Endothelial Growth Factor A	2011
Novel molecular targeted therapies for refractory thyroid cancer. Head & neck, 2012, Volume: 34, Issue:5 Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat	2012
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors]. Magyar onkologia, 2012, Volume: 56, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib	2012
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects]. Magyar onkologia, 2012, Volume: 56, Issue:3 Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays	2012
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status. Angiogenesis, 2014, Volume: 17, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2014
Efficacy of motesanib diphosphate in non-small-cell lung cancer. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Indoles; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Paclitaxel; Protein Kinase Inhibitors; Protein-Tyrosine Kinases	2014
Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. The oncologist, 2015, Volume: 20, Issue:2 Topics: Disease-Free Survival; Humans; Indoles; Iodine Radioisotopes; MAP Kinase Kinase Kinase 1; Niacinamide; Oligonucleotides; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Thyroid Neoplasms	2015
[Anti-angiogenesis and molecular targeted therapies]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2015
Treatment of advanced thyroid cancer: role of molecularly targeted therapies. Targeted oncology, 2015, Volume: 10, Issue:3 Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A	2015
Trial watch: Telomerase inhibitor shows promise in myeloproliferative disorders. Nature reviews. Drug discovery, 2015, Volume: 14, Issue:11 Topics: Animals; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Indoles; Myeloproliferative Disorders; Niacinamide; Oligonucleotides; Telomerase	2015
Telomerase inhibitors: a patent review (2010-2015). Expert opinion on therapeutic patents, 2016, Volume: 26, Issue:6 Topics: Animals; Antineoplastic Agents; Drug Design; Enzyme Inhibitors; Humans; Indoles; Inflammation; Neoplasms; Niacinamide; Oligonucleotides; Patents as Topic; Telomerase	2016

Trials

30 trial(s) available for niacinamide and imetelstat

Article	Year
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jun-10, Volume: 25, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Female; Humans; Hypertension; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Oligonucleotides; Protein Kinase Inhibitors; Treatment Outcome; Vascular Endothelial Growth Factor A	2007
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors. Investigational new drugs, 2008, Volume: 26, Issue:5 Topics: Aged; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Female; Humans; Indoles; Ketoconazole; Male; Middle Aged; Neoplasms; Niacinamide; Oligonucleotides	2008
Motesanib diphosphate in progressive differentiated thyroid cancer. The New England journal of medicine, 2008, Jul-03, Volume: 359, Issue:1 Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Papillary; Female; Genotype; Humans; Indoles; Male; Middle Aged; Niacinamide; Oligonucleotides; Proto-Oncogene Proteins c-kit; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Thyroglobulin; Thyroid Neoplasms	2008
Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. British journal of cancer, 2008, Nov-04, Volume: 99, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Oligonucleotides	2008
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-10, Volume: 27, Issue:23 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Medullary; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Oligonucleotides; Proto-Oncogene Proteins c-kit; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Treatment Outcome	2009
Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate. Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Benzamides; Drug Resistance, Neoplasm; Drug Tolerance; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Japan; Male; Middle Aged; Niacinamide; Oligonucleotides; Piperazines; Pyrimidines; Radiography; Treatment Outcome	2010
Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jan-01, Volume: 16, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Panitumumab; Receptors, Vascular Endothelial Growth Factor	2010
Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:5 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Indoles; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Oligonucleotides; Treatment Outcome	2010
A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, May-01, Volume: 16, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Cohort Studies; Constipation; Dose-Response Relationship, Drug; Fatigue; Female; Hepatocyte Growth Factor; Humans; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasm Staging; Neoplasms; Niacinamide; Oligonucleotides; Treatment Outcome	2010
Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Medullary; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Oligonucleotides; Placenta Growth Factor; Pregnancy Proteins; Thyroid Neoplasms; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2010
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Niacinamide; Oligonucleotides; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome	2011
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Survival Rate	2011
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. The Lancet. Oncology, 2011, Volume: 12, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Double-Blind Method; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Oligonucleotides; Paclitaxel; Receptor, ErbB-2	2011
Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. BMC cancer, 2011, Jul-26, Volume: 11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Hypertension; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Niacinamide; Oligonucleotides; Quinazolines; Treatment Outcome; Venous Thrombosis; Vomiting; Young Adult	2011
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Aug-10, Volume: 30, Issue:23 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Receptors, Vascular Endothelial Growth Factor; Young Adult	2012
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer. Breast cancer research and treatment, 2012, Volume: 135, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Maximum Tolerated Dose; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Proto-Oncogene Proteins c-kit; Receptors, Platelet-Derived Growth Factor; Taxoids; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3	2012
Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer. Clinical pharmacology and therapeutics, 2012, Volume: 92, Issue:5 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Humans; Indoles; Lung Neoplasms; Models, Biological; Niacinamide; Oligonucleotides; Paclitaxel; Proportional Hazards Models; Survival Rate	2012
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecologic oncology, 2013, Volume: 129, Issue:1 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; DNA, Neoplasm; Fallopian Tube Neoplasms; Female; Glial Cell Line-Derived Neurotrophic Factor; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Oligonucleotides; Ovarian Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Vascular Endothelial Growth Factor A	2013
The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. BMC cancer, 2013, May-16, Volume: 13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gallbladder; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Oligonucleotides; Young Adult	2013
A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112). Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-01, Volume: 19, Issue:23 Topics: Adolescent; Antineoplastic Agents; Area Under Curve; Bone Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Leukocytes, Mononuclear; Male; Neoplasm Recurrence, Local; Neuroblastoma; Niacinamide; Oligonucleotides; Sarcoma, Ewing; Telomerase; Treatment Outcome; Young Adult	2013
Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Double-Blind Method; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Proportional Hazards Models; Treatment Outcome; Young Adult	2014
Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Double-Blind Method; Early Termination of Clinical Trials; Female; Hemoptysis; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Survival Rate	2014
Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience. PloS one, 2014, Volume: 9, Issue:10 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Oligonucleotides; Paclitaxel; Placebo Effect; Placenta Growth Factor; Pregnancy Proteins; Proportional Hazards Models; ROC Curve; Survival Rate	2014
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; In Situ Hybridization, Fluorescence; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Niacinamide; Oligonucleotides; Proportional Hazards Models; Telomerase; Telomere	2015
A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Oncotarget, 2014, Nov-30, Volume: 5, Issue:22 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Oligonucleotides; Recombinant Fusion Proteins	2014
Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Middle Aged; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Panitumumab; Young Adult	2015
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. The New England journal of medicine, 2015, Sep-03, Volume: 373, Issue:10 Topics: Aged; Bone Marrow Cells; DNA Mutational Analysis; Drug Administration Schedule; Female; Fibrosis; Humans; Indoles; Infusions, Intravenous; Janus Kinase 2; Male; Middle Aged; Mutation; Niacinamide; Oligonucleotides; Pilot Projects; Polycythemia Vera; Primary Myelofibrosis; Remission Induction; Telomerase; Thrombocythemia, Essential; Transaminases	2015
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. The New England journal of medicine, 2015, Sep-03, Volume: 373, Issue:10 Topics: Aged; Aged, 80 and over; Drug Administration Schedule; Female; Humans; Indoles; Infusions, Intravenous; Janus Kinase 2; Liver; Liver Function Tests; Male; Middle Aged; Mutation; Niacinamide; Oligonucleotides; Pilot Projects; Telomerase; Thrombocythemia, Essential	2015
A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. Journal of neuro-oncology, 2016, Volume: 129, Issue:3 Topics: Adolescent; Alanine Transaminase; Antineoplastic Agents; Blood Cell Count; Central Nervous System Neoplasms; Child; Child, Preschool; Female; Glioma; Humans; Indoles; Lymphocytes; Male; Neoplasm Recurrence, Local; Neutrophils; Niacinamide; Oligonucleotides; Telomerase; Time Factors; Treatment Outcome; Young Adult	2016
Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Nov-10, Volume: 35, Issue:32 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Hong Kong; Humans; Indoles; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Oligonucleotides; Paclitaxel; Republic of Korea; Survival Rate; Treatment Outcome	2017

Other Studies

41 other study(ies) available for niacinamide and imetelstat

Article	Year
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer research, 2006, Sep-01, Volume: 66, Issue:17 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Endothelium, Vascular; Female; Fibroblasts; Humans; Indoles; Leukemia, Megakaryoblastic, Acute; Mice; Mice, Nude; Niacinamide; Oligonucleotides; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Rats; Rats, Sprague-Dawley; Receptors, Vascular Endothelial Growth Factor; Skin; Transplantation, Heterologous; Umbilical Veins	2006
Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour. Gut, 2007, Volume: 56, Issue:7 Topics: Base Sequence; Benzamides; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Middle Aged; Niacinamide; Oligonucleotides; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines	2007
Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma. Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:4 Topics: Administration, Oral; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Humans; Indoles; Male; Neoplasm, Residual; Niacinamide; Oligonucleotides; Pleural Neoplasms; Radiotherapy, Adjuvant; Thymoma; Thymus Neoplasms; Treatment Outcome	2009
Motesanib diphosphate in progressive differentiated thyroid cancer. The New England journal of medicine, 2008, Dec-18, Volume: 359, Issue:25 Topics: Adenocarcinoma, Follicular; Biomarkers, Tumor; Disease Progression; Humans; Indoles; Mitogen-Activated Protein Kinases; Niacinamide; Oligonucleotides; Thyroid Neoplasms	2008
Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jan-01, Volume: 15, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; Humans; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Niacinamide; Oligonucleotides; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-kit; Random Allocation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2009
3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2. Bioorganic & medicinal chemistry letters, 2009, Feb-15, Volume: 19, Issue:4 Topics: Adenosine Triphosphate; Caco-2 Cells; Combinatorial Chemistry Techniques; Drug Design; Humans; Indoles; Molecular Structure; Niacinamide; Oligonucleotides; Phthalazines; Pyridines; Structure-Activity Relationship; Thiazoles; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2	2009
The effects of telomerase inhibition on prostate tumor-initiating cells. International journal of cancer, 2010, Jul-15, Volume: 127, Issue:2 Topics: Cell Line, Tumor; Humans; Indoles; Male; Neoplastic Stem Cells; Niacinamide; Oligonucleotides; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Spheroids, Cellular; Telomerase; Telomere	2010
Forcing tumor stem cells to an end. Neurosurgery, 2010, Volume: 66, Issue:4 Topics: Glioblastoma; Humans; Indoles; Neoplastic Stem Cells; Niacinamide; Oligonucleotides; Stem Cell Transplantation; Vitamin B Complex	2010
Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jul-15, Volume: 16, Issue:14 Topics: Animals; Antineoplastic Agents; Cell Proliferation; Disease Models, Animal; Drug Therapy, Combination; Endothelial Cells; Head and Neck Neoplasms; Humans; Indoles; Male; Mice; Mice, Nude; Neoplasm Transplantation; Niacinamide; Oligonucleotides; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2010
Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors. Journal of experimental & clinical cancer research : CR, 2010, Jul-15, Volume: 29 Topics: Animals; Blotting, Western; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Mice; Mice, Inbred C57BL; Mutation; Niacinamide; Oligonucleotides; Phosphorylation; Proto-Oncogene Proteins c-kit	2010
Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Medullary; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Models, Biological; Niacinamide; Oligonucleotides; Thyroid Neoplasms; Time Factors; Treatment Outcome	2010
Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Models, Statistical; Niacinamide; Oligonucleotides; Thyroid Neoplasms; Treatment Outcome	2010
The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer research, 2010, Nov-15, Volume: 70, Issue:22 Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Flow Cytometry; Humans; Indoles; Mice; Mice, Nude; Neoplastic Stem Cells; Niacinamide; Oligonucleotides; Pancreatic Neoplasms; Telomerase; Xenograft Model Antitumor Assays	2010
Anti-tumor activity of motesanib in a medullary thyroid cancer model. Journal of endocrinological investigation, 2012, Volume: 35, Issue:2 Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cells, Cultured; Female; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Mice; Mice, Nude; Niacinamide; Oligonucleotides; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-ret; Thyroid Neoplasms; Transfection; Xenograft Model Antitumor Assays	2012
Anti-angiogenic therapies in metastatic breast cancer-an unfulfilled dream. The Lancet. Oncology, 2011, Volume: 12, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Oligonucleotides; Paclitaxel; Vascular Endothelial Growth Factor A	2011
Multitargeted tyrosine kinase inhibitors in unselected patients with advanced non-small-cell lung cancer (NSCLC): impressions from MONET (the motesanib NSCLC efficacy and tolerability study). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Aug-10, Volume: 30, Issue:23 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Lung Neoplasms; Male; Niacinamide; Oligonucleotides; Receptors, Vascular Endothelial Growth Factor	2012
Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks. Biochimica et biophysica acta, 2012, Volume: 1823, Issue:12 Topics: Carcinoma, Squamous Cell; Cell Proliferation; DNA Breaks, Double-Stranded; DNA Repair; DNA, Neoplasm; Esophageal Neoplasms; Fluorescent Antibody Technique; Humans; Indoles; Niacinamide; Oligonucleotides; Radiation, Ionizing; Real-Time Polymerase Chain Reaction; Telomerase; Telomere; Tumor Cells, Cultured	2012
Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Molecular cancer, 2012, Sep-19, Volume: 11 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Female; Gene Expression; Humans; Indoles; Lung Neoplasms; Mice; Mice, Nude; Mutation; Niacinamide; Oligonucleotides; Taxoids; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2012
No end in sight for telomerase-targeted cancer drugs. Nature medicine, 2013, Volume: 19, Issue:1 Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Oligonucleotides; Peptide Fragments; Telomerase; Thrombocytosis	2013
Imetelstat (a telomerase antagonist) exerts off‑target effects on the cytoskeleton. International journal of oncology, 2013, Volume: 42, Issue:5 Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytoskeleton; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lung Neoplasms; Matrix Metalloproteinase 2; Mice; Niacinamide; Oligonucleotides; Telomerase; Telomere Homeostasis	2013
Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes. PloS one, 2013, Volume: 8, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Catalytic Domain; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; DNA Helicases; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Leukemic; Histones; Humans; Indoles; Ku Autoantigen; Leukemia, Lymphoid; Middle Aged; Niacinamide; Oligonucleotides; Phosphorylation; Protein Binding; Telomerase; Vidarabine	2013
Exploratory modeling and simulation to support development of motesanib in Asian patients with non-small cell lung cancer based on MONET1 study results. Clinical pharmacology and therapeutics, 2014, Volume: 95, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Computer Simulation; Female; Humans; Indoles; Lung Neoplasms; Male; Models, Biological; Multivariate Analysis; Niacinamide; Oligonucleotides; Prognosis; Randomized Controlled Trials as Topic; Smoking; Survival Rate; Time Factors; Treatment Outcome	2014
Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochemical pharmacology, 2014, Aug-15, Volume: 90, Issue:4 Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Drug Resistance, Multiple; Fluorescent Antibody Technique; Humans; Indoles; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Niacinamide; Oligonucleotides; Paclitaxel; Protein Kinase Inhibitors	2014
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. Acta neuropathologica, 2014, Volume: 128, Issue:6 Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Child, Preschool; Cohort Studies; Disease-Free Survival; Enzyme Inhibitors; Ependymoma; Female; Humans; Indoles; Mice; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Niacinamide; Oligonucleotides; Telomerase; Telomere	2014
Antiangiogenic effects of topically administered multiple kinase inhibitor, motesanib (AMG 706), on experimental choroidal neovascularization in mice. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2015, Volume: 31, Issue:1 Topics: Administration, Topical; Angiogenesis Inhibitors; Animals; Choroid; Choroidal Neovascularization; Fluorescein Angiography; Indoles; Laser Coagulation; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 3; Models, Animal; Niacinamide; Oligonucleotides; Phosphorylation; Protein Kinase Inhibitors	2015
Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor. Cancer genetics, 2014, Volume: 207, Issue:9 Topics: Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Cell Proliferation; Chromosomal Proteins, Non-Histone; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Histones; Humans; Indoles; Mice; Mice, Inbred C57BL; Mice, SCID; Niacinamide; Oligonucleotides; Phosphorylation; Rhabdoid Tumor; SMARCB1 Protein; Telomerase; Telomere Homeostasis; Telomere Shortening; Transcription Factors; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2014
Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell stem cell, 2014, Dec-04, Volume: 15, Issue:6 Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Indoles; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Niacinamide; Oligonucleotides; Recurrence; RNA, Small Interfering; Telomerase; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2014
Role for telomerase in pulmonary hypertension. Circulation, 2015, Feb-24, Volume: 131, Issue:8 Topics: Adult; Animals; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Female; Humans; Hypertension, Pulmonary; Hypoxia; Indoles; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Mutant Strains; Middle Aged; Muscle, Smooth, Vascular; Niacinamide; Oligonucleotides; Pulmonary Artery; Serotonin Plasma Membrane Transport Proteins; Telomerase	2015
The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells. Breast cancer research and treatment, 2015, Volume: 149, Issue:3 Topics: Animals; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Female; Humans; Indoles; Mice; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Niacinamide; Oligonucleotides; Receptor, ErbB-2; Telomerase; Telomere; Trastuzumab; Xenograft Model Antitumor Assays	2015
EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene, 2015, Oct-08, Volume: 34, Issue:41 Topics: Analgesics; Animals; Antibodies, Monoclonal; Apoptosis; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Female; Focal Adhesion Kinase 1; Glioma; Indoles; Mice, Inbred BALB C; Niacinamide; Oligonucleotides; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Receptor Protein-Tyrosine Kinases; Signal Transduction; Transcriptional Activation; Xenograft Model Antitumor Assays	2015
The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma. Cancer biology & therapy, 2015, Volume: 16, Issue:6 Topics: Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; DNA Damage; Enzyme Activation; Enzyme Inhibitors; HSP90 Heat-Shock Proteins; Humans; Indoles; Lactams, Macrocyclic; Mice; Niacinamide; Oligonucleotides; Osteosarcoma; Signal Transduction; Telomerase; Telomere Shortening; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2015
Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase. Journal of molecular modeling, 2015, Volume: 21, Issue:7 Topics: Aminopyridines; Binding Sites; Humans; Indoles; Kinetics; Molecular Docking Simulation; Molecular Dynamics Simulation; Naphthalenes; Niacinamide; Oligonucleotides; Phenylurea Compounds; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Sorafenib; Structural Homology, Protein; Thermodynamics; Vascular Endothelial Growth Factor Receptor-2	2015
Telomerase inhibition improves tumor response to radiotherapy in a murine orthotopic model of human glioblastoma. Molecular cancer, 2015, Jul-17, Volume: 14 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Disease Models, Animal; Glioblastoma; Humans; Indoles; Mice; Niacinamide; Oligonucleotides; Radiation Tolerance; Telomerase; Xenograft Model Antitumor Assays	2015
High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:16 Topics: Angiogenesis Inhibitors; Anilides; Carcinoma, Neuroendocrine; Databases, Chemical; Drug Discovery; Humans; Imidazoles; Indoles; Molecular Docking Simulation; Molecular Structure; Niacinamide; Oligonucleotides; Piperidines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2	2015
Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. Blood cancer journal, 2016, Mar-11, Volume: 6 Topics: Anemia, Refractory; Anemia, Sideroblastic; Combined Modality Therapy; Humans; Indoles; Niacinamide; Oligonucleotides; Thrombocytosis	2016
Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells. Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chickens; Chorioallantoic Membrane; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; HT29 Cells; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Protein Kinase Inhibitors; Thiophenes	2016
Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner. Oncotarget, 2016, May-31, Volume: 7, Issue:22 Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Genotype; Humans; Indoles; Lung Neoplasms; Mice, Inbred NOD; Mice, SCID; Niacinamide; Oligonucleotides; Phenotype; Telomerase; Telomere; Telomere Homeostasis; Telomere Shortening; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays	2016
A case report of motesanib-induced biliary sludge formation causing obstructive cholangitis with acute pancreatitis treated by endoscopic sphincterotomy. Medicine, 2016, Volume: 95, Issue:37 Topics: Adult; Antineoplastic Agents; Bile; Carcinoma, Non-Small-Cell Lung; Cholangitis; Fatal Outcome; Humans; Indoles; Lung Neoplasms; Male; Niacinamide; Oligonucleotides; Pancreatitis; Sphincterotomy, Endoscopic	2016
Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma. Oncotarget, 2017, Feb-21, Volume: 8, Issue:8 Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Indoles; Male; Mice; Mice, Nude; Niacinamide; Oligonucleotides; Random Allocation; Telomerase; Xenograft Model Antitumor Assays	2017
Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis. Leukemia, 2017, Volume: 31, Issue:11 Topics: Enzyme Inhibitors; Humans; Indoles; Megakaryocytes; Niacinamide; Oligonucleotides; Polyploidy; Telomerase	2017
Preventing High Altitude Cerebral Edema in Rats with Repurposed Anti-Angiogenesis Pharmacotherapy. Aerospace medicine and human performance, 2016, Dec-01, Volume: 87, Issue:12 Topics: Acetazolamide; Altitude; Altitude Sickness; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Brain Edema; Capillary Permeability; Carbonic Anhydrase Inhibitors; Cerebral Arteries; Cerebral Veins; Deferoxamine; Indoles; Male; Niacinamide; Oligonucleotides; Rats; Rats, Sprague-Dawley	2016